ImmunityBio (NASDAQ:IBRX – Get Free Report) and enGene (NASDAQ:ENGN – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.
Profitability
This table compares ImmunityBio and enGene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImmunityBio | -8,016.83% | N/A | -110.02% |
| enGene | N/A | -16.69% | -14.27% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for ImmunityBio and enGene, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImmunityBio | 0 | 0 | 4 | 1 | 3.20 |
| enGene | 0 | 1 | 6 | 1 | 3.00 |
Institutional and Insider Ownership
8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 76.8% of ImmunityBio shares are owned by insiders. Comparatively, 10.4% of enGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares ImmunityBio and enGene”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImmunityBio | $31.22 million | 71.52 | -$583.20 million | ($0.58) | -4.36 |
| enGene | N/A | N/A | -$55.14 million | ($1.52) | -2.79 |
enGene has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
ImmunityBio has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500.
Summary
ImmunityBio beats enGene on 7 of the 13 factors compared between the two stocks.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
